Enrollment and background.
parasitemia
MALARIA, PARASITEMIA
Between December 1, 2003, and October 11, 2006, 1,320 women were enrolled in the study and randomized to control (436), monthly SP (441), and AZI-SP groups (443). At enrollment the intervention groups were similar except for small differences in the prevalence of microscopic malaria parasitemia and mean number of previous pregnancies (Baseline characteristics of the participating women at enrollment, by study groupAZI = azithromycin; BMI = body mass index; Hb = hemoglobin; PCR = polymerase chain reaction; SP = sulfadoxine-pyrimethamine.Value missing for one participant.The mean (SD) number of scheduled SP treatments received, among those included in these analyses, was 2.0 (0.2) in the control group, 4.0 (0.9) in the monthly SP group, and 4.0 (0.8) in the AZI-SP group. Women in the AZI-SP group received a mean (SD) of 2.0 (0.2) azithromycin doses. A DBS sample at enrollment and at least once thereafter with all covariate data was available from 97.5% of the participants. Excluding DBS sample at enrollment, the mean (SD) number of DBS samples included in the analyses during the second and third trimesters were 1.4 (0.5) and 2.5 (0.8) samples per participant, respectively, with no difference between groups. Each participant in the monthly ultrasound follow-up group had at least one ultrasound measurement after enrollment (Enrollment, randomization, and follow-up. AZI-SP = intervention group with monthly sulfadoxine-pyrimethamine (SP) and two doses of azithromycin; PCR = polymerase chain reaction.